According to a new market report published by Lucintel, the future of the induced pluripotent stem cell market looks promising with opportunities in the academic research, drug development & toxicity testing, and regenerative medicine applications. The global induced pluripotent stem cell market is expected to grow with a CAGR of 9% from 2020 to 2025. The major drivers for this market are surge in demand for personalized regenerative cell therapies, increasing prevalence of chronic diseases, and rising usage of genome engineering in personalized medicines.
To download report brochure, please go to https://www.lucintel.com/induced-pluripotent-stem-cell-market.aspx and click "download brochure" tab from the menu
Induced pluripotent stem cells (iPSC) are derived from skin or blood cells that have been reprogrammed back into an embryonic-like pluripotent state which enables the development of an unlimited source of any type of human cell required for therapeutic purposes.
Within this market, research laboratories will remain the largest end user segment over the forecast period due to increasing cell-based research & clinical trials.
North America will remain the largest region over the forecast period due to rising number of clinical trials & research and increasing adoption of functional cells for pre-clinical screening of drugs in the region.
Applied StemCell, BlueRock Therapeutics, Corning Life Sciences, Merck Millipore, Lonza, Promega, and Thermo Fisher Scientific are among the major suppliers in the global induced pluripotent stem cell market.
Lucintel, a leading global strategic consulting and market research firm, has analyzed growth opportunities in the global induced pluripotent stem cell market by product function, derived cell-type, application, end user, and region. Lucintel has prepared a comprehensive research report titled “Growth Opportunities in the Global Induced Pluripotent Stem Cell Market 2020-2025: Trends, Forecast, and Opportunity Analysis.” This Lucintel report serves as a catalyst for growth strategy, as it provides comprehensive data and analysis on trends, key drivers, and directions. The study includes trends and forecast for the global induced pluripotent stem cell market by product function, derived cell-type, application, end user, and region as follows:
By Product Function [Value ($ Million) shipment analysis for 2014 – 2025]:
Molecular & Cellular Engineering
Cellular Reprogramming
Cell Culture
Cell Differentiation & Cell Analysis
By Derived Cell-type [Value ($ Million) shipment analysis for 2014 – 2025]:
Keratinocytes
Amniotic Cells
Neuronal Cells
Cardiac (includes fibroblast) and Vascular Cells
Immune Cells
Renal and Liver Cells (includes 1st point)
Others
By Application [Value ($ Million) shipment analysis for 2014 – 2025]:
Academic Research
Drug Development & Toxicity Testing
Regenerative Medicine
By End User [Value ($ Million) shipment analysis for 2014 – 2025]:
Research Laboratories
Biotechnology Companies
Hospitals
By Region [Value ($ Million) shipment analysis for 2014 – 2025]:
United States
Canada
Mexico
United Kingdom
Germany
France
This 150-page research report will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or visit us at helpdesk@lucintel.com.
About Lucintel
Lucintel, the premier global Management Consulting and market research firm, creates winning strategies for growth. It offers market assessments, competitive analysis, opportunity analysis, Growth Consulting, M&A, and Due diligence services to executives and key decision makers in a variety of industries. For further information, visit www.lucintel.com.